US Department of Justice Declines J&J’s Risperdal Settlement
It has been reported that Johnson & Johnson’s bid to resolve alleged claims of illegal marketing of the antipsychotic blockbuster, Risperdal, which could cost the organisation about $1 billion, has been scuppered by the US Department of Justice. A tentative deal between Johnson & Johnson and federal prosecutors in Philadelphia was reached a couple of